Topic
Topic
A Journal of Investigative Dermatology study published October 9, 2026 maps how Wnt/β-catenin pathway components sustain pre–basal cell carcinoma–like cell proliferation and survival.
JAAD published an expert opinion on October 8, 2026 comparing efficacy and tolerability of hedgehog pathway inhibitors for locall…
The FDA has approved a light-based treatment for a common skin cancer, adding a nonsurgical phototherapy option for non-melanoma…
Vismodegib and sonidegib both block Smoothened, yet dosing, tolerability and real-world experience separate the only two FDA-appr…
New Dermatology Times guidance examines how to order hedgehog inhibitors with surgery, radiation and immunotherapy in advanced ba…
CivaTech Oncology of Morrisville announces first commercial use of CivaDerm for non-melanoma skin cancer, moving the device into…
Intralesional BO-112, a TLR3/MDA5-agonist double-stranded RNA complex, shows early promise as a nonsurgical approach for high-ris…
Intralesional BO-112, a TLR agonist, shows early promise as a nonsurgical treatment for high-risk basal cell carcinoma, Dermatolo…
Positive Phase 2b topline results for intralesional BO-112 in localized basal cell carcinoma were presented as a late-breaker at…
FAU researchers combined a 785-nm handheld Raman probe with machine learning to classify BCC, SCC and normal skin at up to 84% ac…